PHARMA OUTSOURCING ARTICLES

• CDMO Partnerships In Early Development Aren’t Always The Best Choice

  This article looks at the needs and challenges biotech organizations face during the manufacture of therapies, how they can reduce cost, and how establishing — or not establishing — partnerships with CDMOs can help get their therapies to patients faster.

• A More Balanced And Stable Future With CDMOs

  Two Industry Experts talk about where they see the outsourcing industry going in the near future.

• 6 Reasons Why India Is The Future Of Global Production Of APIs

  Here is why, in my view, India will be essential to the future of global drug production.

• What Is A Risk-Based Approach To CRO Oversight?

  Ian Wyglendowski, the head of strategic clinical partnering at UCB, recommends taking a risk-based approach to CRO oversight, and gives specifics that you can implement.

• Manufacturing CGTs: Should I Use A CDMO?

  Given the current regulatory framework, manufacturing issues are a major challenge for sponsors of cell and gene therapies. This article shares some key questions and considerations you should ask yourself in order to make the decision whether or not you should use a CDMO.

• 2022 Outsourcing Trends In Biopharmaceutical Manufacturing

  The continued focus on productivity and efficiency is moving manufacturers to increasingly consider outsourcing activities. Biomanufacturers are spending more, demanding better technologies, and expressing greater optimism. This article shares the trends in outsourced activities, percentages of activities outsourced, outsourcing destinations, and offshoring.

• How To Build A Strong CRO Partnership And Find Drug Development Success

  Building a collaborative and highly engaged partnership with a CRO to optimize study enrollment is critical for a company’s success, particularly with so much reliance on virtual interactions. Here are some tips on how to do just that.

• Why I’m Thankful For Sponsors And CROs

  There are many patients out there who depend on those efforts and the amazing medicines that result from them. I am now one of them.

• Takeda’s Mission To Improve Communication With Patients, Sites, And CROs

  Being a better partner for your patients, sites, and CROs begins with effective communication. When Karen Correa joined Takeda as VP, head of global clinical operations, she made improved communications her top priority.

• CRO Oversight Essentials

  Sponsors need to proactively identify and manage the risks involved with working with a CRO. This kind of oversight can help reduce the likelihood of negative consequences that could impact the quality of a trial.